1![1978 Non-adherence is the most important risk factor for ledipasvir/sofosbuvir HCV treatment failure in the real world. Dost Sarpel1, Isaac Wasserman2, Alyssa L. Trochtenberg2, Kian Bichoupan1, David P. Del Bello1, Ponni 1978 Non-adherence is the most important risk factor for ledipasvir/sofosbuvir HCV treatment failure in the real world. Dost Sarpel1, Isaac Wasserman2, Alyssa L. Trochtenberg2, Kian Bichoupan1, David P. Del Bello1, Ponni](https://www.pdfsearch.io/img/0e10d9a50ca577cafbe84d1bb17f5b37.jpg) | Add to Reading ListSource URL: static.coreapps.net- Date: 2016-10-12 15:43:04
|
---|
2![Microsoft Word - GILEAD BRIEFING Microsoft Word - GILEAD BRIEFING](https://www.pdfsearch.io/img/3d23912ac22fcee606c517d8f35a0daf.jpg) | Add to Reading ListSource URL: www.ukts.orgLanguage: English - Date: 2016-07-02 14:50:25
|
---|
3![--------------------------------CONTRAINDICATIONS----------------------------- EPCLUSA and ribavirin combination regimen is contraindicated in patients for whom ribavirin is contraindicated (4) HIGHLIGHTS OF PRESCRIBIN --------------------------------CONTRAINDICATIONS----------------------------- EPCLUSA and ribavirin combination regimen is contraindicated in patients for whom ribavirin is contraindicated (4) HIGHLIGHTS OF PRESCRIBIN](https://www.pdfsearch.io/img/763cd55ea5b173975689fd1ecab036b6.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2016-06-28 12:26:37
|
---|
4![Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English transl Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English transl](https://www.pdfsearch.io/img/5e25dcd4ce32639e0077a9c235b2924a.jpg) | Add to Reading ListSource URL: www.pmda.go.jpLanguage: English - Date: 2016-08-04 23:25:54
|
---|
5![Guidelines EASL Recommendations on Treatment of Hepatitis C 2015 European Association for the Study of the Liver ⇑ Introduction Guidelines EASL Recommendations on Treatment of Hepatitis C 2015 European Association for the Study of the Liver ⇑ Introduction](https://www.pdfsearch.io/img/64f6d0c87fa3afe60bf88e0567400ac0.jpg) | Add to Reading ListSource URL: www.easl.euLanguage: English - Date: 2015-09-08 13:26:17
|
---|
6![State of Illinois Illinois Department of Public Health Ryan White Part B ADAP Medication Assistance Program (MAP) Application for Pre Approval of Hepatitis C Medication Assistance The following medications are n o w avai State of Illinois Illinois Department of Public Health Ryan White Part B ADAP Medication Assistance Program (MAP) Application for Pre Approval of Hepatitis C Medication Assistance The following medications are n o w avai](https://www.pdfsearch.io/img/3188b6ade07392b43a96603a618dabbb.jpg) | Add to Reading ListSource URL: hivcareconnect.comLanguage: English - Date: 2016-05-03 16:46:58
|
---|
7![Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translatio Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translatio](https://www.pdfsearch.io/img/aba8044d13f40a221cd240029f5c6167.jpg) | Add to Reading ListSource URL: www.pmda.go.jpLanguage: English - Date: 2016-08-04 23:27:22
|
---|
8![](https://www.pdfsearch.io/img/bc6d2a75969f649c25f64fc87faca844.jpg) | Add to Reading ListSource URL: www.hepcoalition.orgLanguage: English - Date: 2014-09-26 10:10:18
|
---|
9![SPECIAL AUTHORIZATION REQUEST FORM The Newfoundland and Labrador Prescription Drug Program (NLPDP) Request for Coverage of Harvoni®, Solvadi® and Ibavyr® Pharmaceutical Services Department of Health and Community Serv SPECIAL AUTHORIZATION REQUEST FORM The Newfoundland and Labrador Prescription Drug Program (NLPDP) Request for Coverage of Harvoni®, Solvadi® and Ibavyr® Pharmaceutical Services Department of Health and Community Serv](https://www.pdfsearch.io/img/21ab94da035abda8d79090ada23327ec.jpg) | Add to Reading ListSource URL: www.health.gov.nl.caLanguage: English - Date: 2015-07-10 08:27:35
|
---|
10![0000000000000000002179008 0000000000000000002179008](https://www.pdfsearch.io/img/54a1aaea563fef78e358a96f28e0dcbd.jpg) | Add to Reading ListSource URL: www.gilead.comLanguage: English - Date: 2014-10-10 11:08:31
|
---|